Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo, 71, Modena 41124, Italy.
Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo, 71, Modena 41124, Italy; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
Eur J Intern Med. 2024 Jan;119:53-63. doi: 10.1016/j.ejim.2023.09.009. Epub 2023 Sep 25.
The outcome implications of asymptomatic vs. symptomatic atrial fibrillation (AF) in specific groups of patients according to clinical heart failure (HF) and left ventricular ejection fraction (LVEF) need to be clarified.
In a prospective observational study, patients were categorized according to overt HF with LVEF≤40 %, or with LVEF>40 %, or without overt HF with LVEF40 %≤ or > 40 %, as well as according to the presence of asymptomatic or symptomatic AF.
A total of 8096 patients, divided into 8 groups according to HF and LVEF, were included with similar proportions of asymptomatic AF (ranging from 43 to 48 %). After a median follow-up of 730 [699 -748] days, the composite outcome (all-cause death and MACE) was significantly worse for patients with asymptomatic AF associated with HF and reduced LVEF vs. symptomatic AF patients of the same group (p = 0.004). On adjusted Cox regression analysis, asymptomatic AF patients with HF and reduced LVEF were independently associated with a higher risk for the composite outcome (aHR 1.32, 95 % CI 1.04-1.69) and all-cause death (aHR 1.33, 95 % CI 1.02-1.73) compared to symptomatic AF patients with HF and reduced LVEF. Kaplan-Meier curves showed that HF-LVEF≤40 % asymptomatic patients had the highest cumulative incidence of all-cause death and MACE (p < 0.001 for both).
In a large European cohort of AF patients, the risk of the composite outcome at 2 years was not different between asymptomatic and symptomatic AF in the whole cohort but adverse implications for poor outcomes were found for asymptomatic AF in HF with LVEF≤40 %.
根据临床心力衰竭(HF)和左心室射血分数(LVEF),需要明确特定患者群体中无症状与有症状心房颤动(AF)的结局意义。
在一项前瞻性观察研究中,根据射血分数≤40%的显性心力衰竭或射血分数>40%的心力衰竭,或无显性心力衰竭且 LVEF40%≤或>40%,以及无症状或有症状 AF 的存在,将患者分为不同类别。
共纳入 8096 例患者,根据 HF 和 LVEF 分为 8 组,无症状 AF 的比例相似(范围为 43%至 48%)。中位随访 730[699-748]天后,与同一组中伴有 HF 和 LVEF 降低的有症状 AF 患者相比,伴有 HF 和 LVEF 降低的无症状 AF 患者的复合结局(全因死亡和 MACE)显著更差(p=0.004)。在调整后的 Cox 回归分析中,伴有 HF 和 LVEF 降低的无症状 AF 患者与复合结局(调整后 HR 1.32,95%CI 1.04-1.69)和全因死亡(调整后 HR 1.33,95%CI 1.02-1.73)的风险升高独立相关,与伴有 HF 和 LVEF 降低的有症状 AF 患者相比。Kaplan-Meier 曲线显示,HF-LVEF≤40%的无症状患者的全因死亡和 MACE 累积发生率最高(两者均 p<0.001)。
在一个大型欧洲 AF 患者队列中,整个队列中无症状和有症状 AF 的 2 年复合结局风险无差异,但对于 LVEF≤40%的 HF 患者,无症状 AF 与不良结局相关。